{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:01:21Z","timestamp":1780124481240,"version":"3.54.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373463"],"award-info":[{"award-number":["82373463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["ZSLCYJ202323"],"award-info":[{"award-number":["ZSLCYJ202323"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152811","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:19:37Z","timestamp":1755040777000},"page":"152811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9809-5246","authenticated-orcid":false,"given":"Xue","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-4206","authenticated-orcid":false,"given":"Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0001","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: clinical features and pathogenesis","volume":"87","author":"Jerjen","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10373","key":"10.1016\/j.semarthrit.2025.152811_bib0002","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0003","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)62362-0","article-title":"Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts","volume":"166","author":"Mimura","year":"2005","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0006","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.39865","article-title":"Review: frontiers of antifibrotic therapy in systemic sclerosis","volume":"69","author":"Distler","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152811_bib0007","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","article-title":"Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy","volume":"10","author":"Wei","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"26","key":"10.1016\/j.semarthrit.2025.152811_bib0009","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial Lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0011","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00002281-200211000-00009","article-title":"Pathogenesis of fibrosis: role of TGF-beta and CTGF","volume":"14","author":"Ihn","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"18","key":"10.1016\/j.semarthrit.2025.152811_bib0012","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200005043421807","article-title":"Role of transforming growth factor beta in human disease","volume":"342","author":"Blobe","year":"2000","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/wrr.12398","article-title":"Transforming growth factor beta (TGF-\u03b2) isoforms in wound healing and fibrosis","volume":"24","author":"Lichtman","year":"2016","journal-title":"Wound Repair Regen"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0014","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.biocel.2007.08.016","article-title":"Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3","volume":"40","author":"Ask","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152811_bib0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022293","article-title":"TGF-\u03b21 signaling and tissue fibrosis","volume":"10","author":"Kim","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0016","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor-\u03b2 in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"J Exp Med"},{"issue":"605","key":"10.1016\/j.semarthrit.2025.152811_bib0017","doi-asserted-by":"crossref","first-page":"eabe0407","DOI":"10.1126\/scitranslmed.abe0407","article-title":"TGF\u03b22 and TGF\u03b23 isoforms drive fibrotic disease pathogenesis","volume":"13","author":"Sun","year":"2021","journal-title":"Sci Transl Med"},{"issue":"s1","key":"10.1016\/j.semarthrit.2025.152811_bib0018","doi-asserted-by":"crossref","first-page":"s38","DOI":"10.1111\/j.1524-475X.2011.00711.x","article-title":"Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring","volume":"19","author":"Occleston","year":"2011","journal-title":"Wound Repair Regen"},{"issue":"9671","key":"10.1016\/j.semarthrit.2025.152811_bib0019","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(09)60322-6","article-title":"Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I\/II studies","volume":"373","author":"Ferguson","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0020","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/PRS.0b013e3181ef8e66","article-title":"Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"126","author":"Bush","year":"2010","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0021","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/PRS.0b013e318217429b","article-title":"Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial","volume":"128","author":"So","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/wrr.12182","article-title":"Antiscarring pharmaceuticals: lost in translation?","volume":"22","author":"Agren","year":"2014","journal-title":"Wound Repair Regen"},{"issue":"6958","key":"10.1016\/j.semarthrit.2025.152811_bib0023","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0024","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022129","article-title":"Non-smad signaling pathways of the TGF-\u03b2 Family","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40169-016-0117-2","article-title":"JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers","volume":"5","author":"van der Velden","year":"2016","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.matbio.2017.12.009","article-title":"Thrombospondin-1 regulation of latent TGF-\u03b2 activation: a therapeutic target for fibrotic disease","volume":"68-69","author":"Murphy-Ullrich","year":"2018","journal-title":"Matrix Biol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0027","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.4049\/jimmunol.175.11.7708","article-title":"Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts","volume":"175","author":"Asano","year":"2005","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0028","doi-asserted-by":"crossref","first-page":"8927","DOI":"10.3390\/ijms24108927","article-title":"\u03b1v\u03b23 Integrin as a link between the development of fibrosis and thyroid hormones in systemic sclerosis","volume":"24","author":"Kohon","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"288","key":"10.1016\/j.semarthrit.2025.152811_bib0029","doi-asserted-by":"crossref","first-page":"288ra79","DOI":"10.1126\/scitranslmed.aaa5094","article-title":"The \u03b1v\u03b21 integrin plays a critical in vivo role in tissue fibrosis","volume":"7","author":"Reed","year":"2015","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005017","article-title":"Cross talk among TGF-\u03b2 signaling pathways, integrins, and the extracellular matrix","volume":"3","author":"Munger","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0031","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/CS20171426","article-title":"Dual \u03b1v\u03b23 and \u03b1v\u03b25 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis","volume":"132","author":"Bagnato","year":"2018","journal-title":"Clin Sci (L)"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0032","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: a phase II study of abituzumab in patients with systemic sclerosis\u2013associated interstitial Lung disease","volume":"48","author":"Khanna","year":"2021","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152811_bib0033","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152811_bib0034","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/annrheumdis-2020-eular.1753","article-title":"Thu0329 Safety, target engagement, and initial efficacy of Avid200, a first-in-class potent and isoform-selective inhibitor of Tgf-Beta 1 and 3, in patients with Diffuse cutaneous systemic sclerosis (dcssc): A phase 1 dose escalation study","volume":"79","author":"Lafyatis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41374-017-0014-3","article-title":"Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro","volume":"98","author":"Hall","year":"2018","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152811_bib0036","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0037","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10787-022-01027-6","article-title":"Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals","volume":"30","author":"Al-kuraishy","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"18","key":"10.1016\/j.semarthrit.2025.152811_bib0038","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1074\/jbc.270.18.10618","article-title":"Processing of transforming growth factor beta 1 precursor by human furin convertase","volume":"270","author":"Dubois","year":"1995","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0039","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3390\/biom11101424","article-title":"Effect of Pirfenidone on TGF-\u03b21-induced myofibroblast differentiation and extracellular matrix homeostasis of Human orbital fibroblasts in graves\u2019 Ophthalmopathy","volume":"11","author":"Wu","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2466-12-24","article-title":"Pirfenidone inhibits TGF-\u03b21-induced over-expression of collagen type I and heat shock protein 47 in A549 cells","volume":"12","author":"Hisatomi","year":"2012","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0041","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol Med"},{"issue":"18","key":"10.1016\/j.semarthrit.2025.152811_bib0042","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1111\/jcmm.16821","article-title":"Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-\u03b21\/Smad3 pathway","volume":"25","author":"Ying","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152811_bib0043","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0044","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 Family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"51","key":"10.1016\/j.semarthrit.2025.152811_bib0045","doi-asserted-by":"crossref","first-page":"32635","DOI":"10.1074\/jbc.271.51.32635","article-title":"Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation","volume":"271","author":"Mosley","year":"1996","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152811_bib0046","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/labinvest.2014.81","article-title":"Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 dysregulation in lungs of fibrosis-resistant BALB\/c mice","volume":"94","author":"Wong","year":"2014","journal-title":"Lab Invest"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152811_bib0047","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/emmm.201100604","article-title":"Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis","volume":"4","author":"O\u2019Donoghue","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0048","unstructured":"Oncostatin M As a potential molecular target in systemic sclerosis. ACR Meeting Abstracts. Accessed June 16, 2025. https:\/\/acrabstracts.org\/abstract\/oncostatin-m-as-a-potential-molecular-target-in-systemic-sclerosis\/."},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152811_bib0049","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/rheumatology\/38.7.612","article-title":"Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis","volume":"38","author":"Hasegawa","year":"1999","journal-title":"Rheumatol (Oxf)"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0050","first-page":"308","article-title":"Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis","volume":"25","author":"Hasegawa","year":"1998","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.151964","article-title":"Increased levels of the soluble oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in systemic sclerosis patients and associations with clinical parameters","volume":"225","author":"de Almeida","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120177","article-title":"Soluble oncostatin M receptor (sOSMR): a potential biomarker in systemic sclerosis diagnosis","volume":"569","author":"Constantino Cunha","year":"2025","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0053","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/rheumatology\/keac300","article-title":"Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis","volume":"62","author":"Denton","year":"2022","journal-title":"Rheumatol (Oxf)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0054","first-page":"61","article-title":"Oncostatin M binds the high-affinity leukemia inhibitory factor receptor","volume":"4","author":"Gearing","year":"1992","journal-title":"New Biol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.3246","article-title":"Predicting the long-term effects of therapeutic neutralization of Oncostatin M on Human hematopoiesis","volume":"116","author":"Thorsted","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152811_bib0056","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","article-title":"Two pathways for lysophosphatidic acid production","volume":"1781","author":"Aoki","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0057","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0058","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.30262","article-title":"Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma","volume":"63","author":"Castelino","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0059","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/art.39797","article-title":"An autotaxin\/lysophosphatidic acid\/interleukin-6 amplification loop drives scleroderma fibrosis","volume":"68","author":"Castelino","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0060","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/art.42477","article-title":"A 24-week, phase IIa, randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous systemic sclerosis","volume":"75","author":"Khanna","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0061","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0062","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/exd.12256","article-title":"Bleomycin inhibits adipogenesis and accelerates fibrosis in the subcutaneous adipose layer through TGF-\u03b21","volume":"22","author":"Ohgo","year":"2013","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0063","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/art.30312","article-title":"Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?","volume":"63","author":"Wei","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152811_bib0064","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.38990","article-title":"Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors","volume":"67","author":"Marangoni","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0065","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPARgamma","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/289867","article-title":"PPAR\u03b3 signaling mediates the evolution, development, homeostasis, and repair of the lung","volume":"2012","author":"Rehan","year":"2012","journal-title":"PPAR Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0067","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1242\/dev.099747","article-title":"Fgf10-positive cells represent a progenitor cell population during lung development and postnatally","volume":"141","author":"El Agha","year":"2014","journal-title":"Development"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013778","article-title":"PPAR\u03b3 downregulation by TGF\u00df in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0069","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-018-1630-z","article-title":"Adipocyte-specific repression of PPAR-gamma by NCoR contributes to scleroderma skin fibrosis","volume":"20","author":"Korman","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152811_bib0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.20104","article-title":"Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma","volume":"50","author":"Ghosh","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0071","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1165\/rcmb.2009-0445OC","article-title":"Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells","volume":"45","author":"Zhu","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0072","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0073","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11926-020-00918-3","article-title":"Current and potential new targets in systemic sclerosis therapy: a new hope","volume":"22","author":"Hinchcliff","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0074","article-title":"PPAR\u03b3 partial agonist LPSF\/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients","author":"de Almeida","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10067-016-3535-z","article-title":"Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature","volume":"36","author":"Giuggioli","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"19","key":"10.1016\/j.semarthrit.2025.152811_bib0076","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.3390\/nu14193908","article-title":"Vitamin D in systemic sclerosis: a review","volume":"14","author":"Perazzi","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0077","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9782994","article-title":"Role of vitamin D in systemic sclerosis: a systematic literature review","volume":"2021","author":"Diaconu","year":"2021","journal-title":"J Immunol Res"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0078","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2011.02.002","article-title":"Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature","volume":"10","author":"Arnson","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0079","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/ijms17122103","article-title":"Skin involvement and pulmonary hypertension are associated with vitamin D insufficiency in scleroderma","volume":"17","author":"Atteritano","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0080","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/jcm7120558","article-title":"Fibroblast growth factor 23 to Alpha-Klotho index correlates with systemic sclerosis activity: a proposal for novel disease activity marker","volume":"7","author":"Kotyla","year":"2018","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0081","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3899\/jrheum.110695","article-title":"Significantly decreased serum 25-hydroxyvitamin d levels in a large german systemic sclerosis cohort","volume":"38","author":"Gambichler","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0082","first-page":"50","article-title":"Low vitamin D status in systemic sclerosis and the impact on disease phenotype","volume":"3","author":"Groseanu","year":"2016","journal-title":"Eur J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0083","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/biom11111624","article-title":"The effects of vitamin D on immune system and inflammatory diseases","volume":"11","author":"Ao","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0084","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204378","article-title":"Vitamin D receptor regulates TGF-\u03b2 signalling in systemic sclerosis","volume":"74","author":"Zerr","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106273","article-title":"Vitamin D attenuates elevated oxidative DNA damage in scleroderma patients with organ involvement: A prospective study","volume":"229","author":"Dal-Bekar","year":"2023","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0086","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.arcmed.2019.09.006","article-title":"Associations of vitamin D receptor single nucleotide polymorphisms with susceptibility to systemic sclerosis","volume":"50","author":"Li","year":"2019","journal-title":"Arch Med Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0087","first-page":"1024","article-title":"Vitamin D levels and potential impact in systemic sclerosis","volume":"29","author":"Vacca","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179062","article-title":"Vitamin D deficiency and clinical correlations in systemic sclerosis patients: a retrospective analysis for possible future developments","volume":"12","author":"Trombetta","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0089","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1067\/mjd.2000.108369","article-title":"Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma","volume":"43","author":"Hulshof","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2340\/0001555573449451","article-title":"Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial","volume":"73","author":"Humbert","year":"1993","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112705","article-title":"The roles of orphan nuclear receptor 4 group A1 and A2 in fibrosis","volume":"139","author":"Gao","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0092","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm.3777","article-title":"Orphan nuclear receptor NR4A1 regulates transforming growth factor-\u03b2 signaling and fibrosis","volume":"21","author":"Palumbo-Zerr","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0093","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gutjnl-2011-300783","article-title":"The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating wnt signalling","volume":"61","author":"Chen","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0094","doi-asserted-by":"crossref","first-page":"G280","DOI":"10.1152\/ajpgi.00338.2019","article-title":"Nr4A1 modulates inflammation-associated intestinal fibrosis and dampens fibrogenic signaling in myofibroblasts","volume":"321","author":"Pulakazhi Venu","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0095","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s10020-024-01030-3","article-title":"SPDEF ameliorates UUO-induced renal fibrosis by transcriptional activation of NR4A1","volume":"30","author":"Wang","year":"2024","journal-title":"Mol Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0096","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.jid.2019.04.006","article-title":"Intervention of inflammatory monocyte activity limits dermal fibrosis","volume":"139","author":"Haub","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0097","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/art.42319","article-title":"Nuclear receptor subfamily 4A signaling as a key disease pathway of CD1c+\u2009dendritic cell dysregulation in systemic sclerosis","volume":"75","author":"Servaas","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0098","first-page":"607","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0099","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/art.27642","article-title":"Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis","volume":"62","author":"Marquart","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-016-0373-0","article-title":"Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung","volume":"17","author":"Lucattelli","year":"2016","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0101","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.lfs.2005.05.055","article-title":"Cannabinoid signalling","volume":"78","author":"Demuth","year":"2006","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/glia.20907","article-title":"Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1\/2, JNK, and NF-kappaB","volume":"58","author":"Correa","year":"2010","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0104","doi-asserted-by":"crossref","DOI":"10.1038\/srep21703","article-title":"The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways","volume":"6","author":"del R\u00edo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.apha.2017.03.008","article-title":"The role of nuclear hormone receptors in cannabinoid function","volume":"80","author":"Pistis","year":"2017","journal-title":"Adv Pharmacol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0106","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"13","key":"10.1016\/j.semarthrit.2025.152811_bib0107","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0108","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of Lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152811_bib0109","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of Lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","article-title":"Cannabinoid derivatives acting as dual ppar\u03b3\/CB2 agonists as therapeutic agents for systemic sclerosis","volume":"163","author":"Garc\u00eda-Mart\u00edn","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152811_bib0111","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152811_bib0112","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol Chem"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152811_bib0113","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"36","key":"10.1016\/j.semarthrit.2025.152811_bib0114","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1002\/anie.201302588","article-title":"The chemistry and biology of soluble guanylate cyclase stimulators and activators","volume":"52","author":"Follmann","year":"2013","journal-title":"Angew Chem Int Engl"},{"issue":"SI","key":"10.1016\/j.semarthrit.2025.152811_bib0115","doi-asserted-by":"crossref","first-page":"SI125","DOI":"10.1093\/rheumatology\/keac433","article-title":"Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells","volume":"62","author":"Romano","year":"2023","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0116","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152811_bib0117","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical tgf\u03b2 signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0118","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","article-title":"Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0119","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212489","article-title":"Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators","volume":"77","author":"Matei","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0120","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","article-title":"Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies","volume":"74","author":"Dees","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0121","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.rmed.2016.09.011","article-title":"RISE-SSc: riociguat in diffuse cutaneous systemic sclerosis","volume":"122","author":"Distler","year":"2017","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0122","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0123","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2665-9913(23)00271-0","article-title":"Riociguat in systemic sclerosis: challenges in crossing the bridge from bench to bedside","volume":"5","author":"de Vries-Bouwstra","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0124","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2665-9913(23)00238-2","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial","volume":"5","author":"Distler","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fgene.2016.00095","article-title":"Melanocortin 1 receptor: structure, function, and regulation","volume":"7","author":"Wolf Horrell","year":"2016","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.06.022","article-title":"Targeting melanocortin receptors as potential novel therapeutics","volume":"111","author":"Getting","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0127","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-022-02899-3","article-title":"Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis","volume":"24","author":"Kondo","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2010.11.040","article-title":"Melanocortin MC\u2081 receptor in human genetics and model systems","volume":"660","author":"Beaumont","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.tips.2015.07.007","article-title":"Resolution pharmacology: opportunities for therapeutic innovation in inflammation","volume":"36","author":"Perretti","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152811_bib0130","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/exd.12409","article-title":"Bleomycin-induced fibrosis in MC1 signalling-deficient C57BL\/6J-Mc1r(e\/e) mice further supports a modulating role for melanocortins in collagen synthesis of the skin","volume":"23","author":"B\u00f6hm","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0131","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3389\/fimmu.2018.02571","article-title":"Fibrosis development in HOCl-induced systemic sclerosis: a multistage process hampered by mesenchymal stem cells","volume":"9","author":"Maria","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0132","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.41267","article-title":"Pathogenic activation of mesenchymal stem cells is induced by the disease microenvironment in systemic sclerosis","volume":"72","author":"Taki","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0133","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12016-016-8552-9","article-title":"Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis","volume":"52","author":"Maria","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0134","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.biochi.2013.04.017","article-title":"Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes","volume":"95","author":"Maumus","year":"2013","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/annrheumdis-2018-214218","article-title":"Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis","volume":"78","author":"Magalon","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0136","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10020-023-00630-9","article-title":"Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-\u03b2-SMAD2\/3 pathway","volume":"29","author":"Xu","year":"2023","journal-title":"Mol Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152811_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0138","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2016.03.013","article-title":"Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis","volume":"70","author":"Maria","year":"2016","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0139","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1479-5876-9-181","article-title":"Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells","volume":"9","author":"Ra","year":"2011","journal-title":"J Transl Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0140","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00266-020-01848-2","article-title":"Autologous fat grafting for the oral and digital complications of systemic sclerosis: results of a prospective study","volume":"44","author":"Pignatti","year":"2020","journal-title":"Aesth Plast Surg"},{"issue":"24","key":"10.1016\/j.semarthrit.2025.152811_bib0141","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0142","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/annrheumdis-2019-215770","article-title":"Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures","volume":"78","author":"Assassi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0143","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0144","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study","volume":"79","author":"van Bijnen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0145","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"Pendergrass","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152811_bib0146","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/jid.2012.67","article-title":"Toward personalized medicine in Scleroderma: classification of scleroderma patients into stable \u201cinflammatory\u201d and \u201cfibrotic\u201d subgroups","volume":"132","author":"Leask","year":"2012","journal-title":"J Investig Dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0147","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152811_bib0148","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10038","key":"10.1016\/j.semarthrit.2025.152811_bib0149","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152811_bib0150","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard-2023-224184","article-title":"Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups","volume":"82","author":"Clark","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0151","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1093\/rheumatology\/keab273","article-title":"Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients","volume":"60","author":"Suleman","year":"2021","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0152","unstructured":"Effect of Anti-topoisomerase I antibody status on decline in lung function in patients with systemic sclerosis-associated interstitial Lung Disease: data from the SENSCIS trial. ACR Meeting abstracts. Accessed June 16, 2025. https:\/\/acrabstracts.org\/abstract\/effect-of-anti-topoisomerase-i-antibody-status-on-decline-in-lung-function-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-data-from-the-senscis-trial\/."},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0153","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152811_bib0154","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, Phase II study of the safety and tolerability of Pirfenidone in patients with scleroderma-associated interstitial Lung Disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152811_bib0155","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/bcp.13669","article-title":"In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody","volume":"84","author":"Reid","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0157","unstructured":"Targeting plasmacytoid dendritic cells improves cutaneous Lupus erythematosus skin lesions and reduces type I interferon levels: results of a phase 1 study of VIB7734. ACR Meeting Abstracts. Accessed October 28, 2023. https:\/\/acrabstracts.org\/abstract\/targeting-plasmacytoid-dendritic-cells-improves-cutaneous-lupus-erythematosus-skin-lesions-and-reduces-type-i-interferon-levels-results-of-a-phase-1-study-of-vib7734\/."},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152811_bib0158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289594","article-title":"Adipose derived stromal vascular fraction and fat graft for treating the hands of patients with systemic sclerosis. A randomized clinical trial","volume":"18","author":"Iglesias","year":"2023","journal-title":"PLoS One"},{"issue":"9790","key":"10.1016\/j.semarthrit.2025.152811_bib0159","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European society for blood and marrow transplantation autoimmune disease working party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0161","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13075-017-1373-2","article-title":"Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis","volume":"19","author":"Zhang","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152811_bib0162","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152811_bib0163","series-title":"Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis","author":"Georges","year":"2018"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152811_bib0164","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:02:47Z","timestamp":1780120967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":163,"alternative-id":["S0049017225001829"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152811","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152811"}}